media – Page 602 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Study shows how gut bacteria may trigger MS

Alterations in gut bacteria at a young age could help to trigger and progress multiple sclerosis in people who are genetically predisposed to the autoimmune disease.
- Source: medicalnewstoday
- 495
- November 22, 2017
multiple sclerosis Researches
Study reveals what depression, anxiety look like in the brain

People with depression and social anxiety have some common and specific structural abnormalities in their brains that can be spotted in imaging scans.
- Source: drugdu
- 510
- November 22, 2017
Depression Researches
Meeting the Internet of Medical Things’ Demands for Networking

More connected medical devices are coming online every day, reshaping the way that healthcare networks are designed, used and secured.
- Source: healthtechmagazine.net
- 449
- November 22, 2017
Internet of Things Researches
Stanford, NCI Researchers Discover New CAR-T Target With Early Study Data

Researchers at Stanford University School of Medicine with the National Cancer Institute (NCI) have identified another cancer-surface molecule, CD22, and begun trials on B-cell acute lymphoblastic leukemia (ALL) patients using an immuno-oncology approach similar to CAR-T. In the Phase I trial, 15 of the 21 patients who had previously relapsed or did not respond to anti-CD19 CAR-T, were treated with an anti-CD22 CAR-T therapy. Ten of the 15 patients had already received treatment for CD19-targeted treatment.
- Source: biospace
- 573
- November 22, 2017
cancer CAR–T immuno-oncology Researches
FDA approves first two-drug regimen for certain patients with HIV

The U.S. Food and Drug Administration(FDA) today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.
- Source: finance.yahoo
- 476
- November 22, 2017
FDA HIV immunodeficiency Juluca New Approvals
Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

Encouraged by evidence of the impact that its diabetes drug semaglutide can have on obesity, with patients shedding an average of 16% of their weight in a mid-stage study, top researchers at Novo Nordisk today unveiled an ambitious late-stage strategy to make their mark in a tough, but potentially blockbuster market.
- Source: endpts
- 563
- November 22, 2017
Company Insight Novo Nordisk semaglutide
NHS England consults on simplifying research processes

NHS England says it is planning to accelerate the NHS’ national research strategy, “cutting bureaucracy and speeding up access to new and innovative treatments”.
- Source: Pharmatimes
- 455
- November 22, 2017
NHS polices
FDA OKs Genentech’s Gazyva for Untreated Follicular Lymphoma

Twice on Thursday, Genentech, scored two approvals from the U.S. Food and Drug Administration(FDA) – a new medicine for hemophilia and an expansion for its cancer drug Gazyva.
- Source: Biospace
- 595
- November 21, 2017
cancer FDA hemophilia lymphoma New Approvals
Japan’s PeptiDream Bags $1.11B+ R&D Pact With Bayer

Peptidream Inc. has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
- Source: Biospace
- 506
- November 21, 2017
Market Views PDC PDPS peptide-based
CRISPR shows potential to reduce diseases spread by mosquitoes

Researchers at the University of California, Riverside, have shown that it is possible for transgenic mosquitos to stably express the Cas9 enzyme in their germline. Cas9 addition will allow the utilization of the CRISPR gene editing tool to carry out efficient and highly targeted changes to the DNA of the mosquitoes.
- Source: news-medical
- 532
- November 21, 2017
CAS9 CRISPR DNA enzyme Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.